ALVIO — Valerio Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €195.03m
- €201.58m
- €2.57m
Brief: Onxeo Receives U.S. Patent And Trademark Office Notice Of Allowance For New Patent Protecting Asidna™
Brief: Onxeo Receives EPO Intent-To-Grant Notice For New Patent
Brief: Onxeo Announces Positive Intermediate Results From First Part Of DRIIV-1B Study Evaluating Asidna™ In Combination With Chemotherapy
Brief: Onxeo H1 Current Operating Loss Widens To 6.9 Million Euros
Brief: Onxeo Expands Its Pipeline With New Optimized Lead Ox401 Entering Proof-Of-Concept Preclinical Phase
Brief: Onxeo: Final Positive Data From DRIIV-1 Phase 1 Study Of AsiDNA
Brief: Onxeo Announces Treatment Of First Patient In DRIIV-1b
Brief: Onxeo Publishes Cash Position Of 11.3 Million Euros At Year End
Brief: Onxeo Identifies Predictive Biomarkers For AsiDNA
Brief: Onxeo Receives EPO Intent-to-Grant Notice for New Patent Protecting AsiDNA in Combination with Any PARP Inhibitor
Brief: Onxeo Reports Decision From Paris Court Of Appeal In Lawsuit Against SpeBio/SpePharm
Brief: Onxeo Announces Positive Interim Results From Phase 1 Study Of AsiDNA
Brief: Onxeo Q3 Revenues Reach 3.3 Million Euros
Brief: Onxeo H1 Net Loss Eur 8.8 Million
Brief: Onxeo Announces New Preclinical Results On AsiDNA
Brief: Onxeo Implements Equity Line Financing With Nice & Green
Brief: Onxeo Secures $7.5 Million Of Non-Dilutive Capital From Swk Holdings Corporation
Brief: Onxeo Publishes A Cash Position Of Eur 9.2 Million At March 31, 2018
Brief: Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA